^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CYAD-101

    i
    Company:
    Celyad Oncology
    Drug class:
    NKG2DL-targeted CAR-T immunotherapy
    Related drugs: